Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment (SONAR)

Bayer

Status: Completed

Conditions: Hypertension

Treatments: Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)

Study type: Observational

Funder types: Industry

Identifiers

NCT00932867

14327 - KL0711RO

14010 - KL0711SK

14010

Details and patient eligibility

About

Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment

Enrollment: 3,114 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients over 18 years of age
• Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)
• Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation)

Inclusion criteria for the control arm (treated by ACEi):

• Patients over 18 years of age
• Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)
• Patients, who tolerate ACEi treatment

Exclusion criteria

• Cholestasis, severe hepatic insufficiency
• Allergy to telmisartan
• Gravidity or lactation

Exclusion criteria for the arm of patient treated by ACEi:

• Cholestasis, severe hepatic insufficiency
• Allergy to ACEi
• Gravidity or lactation

Trial design

3,114 participants in 1 patient group

Group 1

Treatment:

Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)